Horizon agrees licensing deal over anti-inflammatory drug
Drugs company Horizon Pharma has agreed to settle a patent dispute centring on a proposed generic version of its anti-inflammatory drug Pennsaid (diclofenac sodium topical solution).
In a statement on Tuesday, September 15, Horizon announced it had agreed a settlement and licensing deal with Taro Pharmaceutical Industries, putting an end to the companies’ dispute.
Horizon sued Taro in July last year at the US District Court for the District of New Jersey in a complaint centring on Taro’s Abbreviated New Drug Application to market a generic version of the drug.
Under the settlement, Horizon and its subsidiaries have granted Taro a non-exclusive licence to manufacture and commercialise the generic version of Pennsaid in the US after January 10, 2029.
However, Taro may be able to enter the market earlier in certain circumstances, Horizon said.
According to Horizon the pair has agreed to submit the settlement agreement to the US Federal Trade Commission and Department of Justice for review.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk